Life SciencesLiability
Contact

TL;DR

Five CDMO insurance program archetypes that Texas pharmaceutical and medical device contract manufacturers use in 2026, organized by sponsor concentration, product class, and revenue stage. Each archetype has different premium ranges, structural tradeoffs, and sponsor MSA fit. The "best" program is the one that matches the operator's actual sponsor portfolio, product mix, and revenue stage - not a one-size-fits-all template.

2026 program archetypes

Best CDMO Insurance Program Structures - Texas 2026

There is no single "best" insurance program for a Texas CDMO. The right program structure depends on sponsor concentration, product class, and revenue stage, and the wrong structure at any of those dimensions creates either coverage gaps at sponsor MSA review or premium spend disproportionate to the actual exposure. Below are the five archetype structures most common across the Texas CDMO segment in 2026, with premium ranges and structural tradeoffs.

01

CDMOs deriving 60%+ revenue from one sponsor; common at $5M-$20M revenue.

Single-sponsor anchor program

· Products liability tower sized to the single sponsor MSA demand (typically $5M-$10M), plus a 50% buffer for renewal-cycle sponsor demand changes.

· Per-project aggregate endorsement built around the sponsor relationship; standard general aggregate is unnecessary given the concentration.

· Cyber and D&O sized to operator-side exposure independently of sponsor demand.

· Recall coverage at $1M-$3M, dedicated first-party.

· IP and tech E&O sized to development services scope.

Typical Texas premium: $45K-$85K annually for a Texas operator at $5M-$20M revenue.

02

CDMOs with 4+ active sponsors, no concentration above 25%; common at $20M-$75M revenue.

Multi-sponsor distributed program

· Products liability tower sized to the largest sponsor MSA demand across the portfolio, with per-location aggregate endorsements to prevent cross-sponsor aggregate exhaustion.

· Multi-sponsor additional-insured architecture - blanket AI endorsement rather than scheduled-list AI.

· Recall coverage at $3M-$5M, sized to the largest sponsor demand.

· Cyber sized to total patient data and DMF exposure across sponsors.

· D&O architecture standard for the operating entity.

Typical Texas premium: $85K-$180K annually for a Texas operator at $20M-$75M revenue.

03

CDMOs manufacturing biologics, sterile injectables, or oncology drug substance; product class is the driver.

Biologic / sterile injectable program

· Products liability tower at $10M minimum, typically $15M-$25M with biologic-specific underwriting.

· cGMP property coverage with explicit validation extension - biologic validation losses can mean months of revalidation downtime.

· Cargo/warehouseman's legal liability for sponsor API and finished biologic.

· Recall coverage at $5M+, dedicated.

· Cyber for sponsor DMF data flows specific to biologic processes.

· IP and tech E&O at elevated limits given biologic process complexity.

Typical Texas premium: $120K-$280K annually for a Texas biologic CDMO at $15M-$50M revenue.

04

CDMOs manufacturing Class III medical devices or contract sterilizing them.

Class III medical device CDMO program

· Products liability tower at $25M minimum, typically $25M-$50M, occurrence-form preferred due to long implantable claim tails.

· MDR liability extension for postmarket reporting obligations.

· GPO supplier insurance endorsements for hospital purchase contract compliance.

· Cyber for device connectivity and patient telemetry exposure.

· IP and tech E&O for device design contributions.

Typical Texas premium: $180K-$400K annually for a Texas Class III device CDMO at $20M-$75M revenue.

05

CDMOs at clinical-stage product mix, $2M-$8M revenue, often providing development services more than commercial manufacturing.

Development-stage / early CDMO program

· Products liability tower at $5M with first-dollar defense provisions; products risk lower at clinical-stage volume.

· Professional liability for development services at $2M-$5M - the primary exposure at clinical-stage.

· Cyber sized to sponsor DMF and clinical data exposure.

· D&O for VC-backed governance if applicable.

· Recall coverage at $1M minimum for any commercial-scale work.

Typical Texas premium: $35K-$65K annually for a Texas early-stage CDMO at $2M-$8M revenue.

How to pick the right archetype

Start with sponsor concentration analysis: if more than 60% of revenue comes from one sponsor, archetype 01 is likely correct. If less than 25% from any sponsor, archetype 02. Then layer product class: biologic or sterile injectable forces archetype 03 regardless of sponsor pattern; Class III device forces archetype 04. For development-stage operators without commercial revenue, archetype 05 applies until commercial transition.

CDMO program structure review

A specialist will reach out by end of business day.

Request a coverage review